Answers are grounded in this paper and cite their sources.
Systematic review shows CFTR modulators benefit sinonasal disease in cystic fibrosis, indicating their therapeutic value.
This review demonstrates that CFTR modulators provide significant benefits for sinonasal disease in CF, reinforcing their role as a comprehensive therapeutic approach addressing both upper airway and systemic disease burdens.
No takes yet. Share an insight, caveat, or question.
Gallardo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: